7-chloro-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-ol | 1287312-59-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃吡啶类
• 英文名称: 7-chloro-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-ol
• CAS: 1287312-59-7
• 化学式: C₈H₈ClNO₂
• 分子量: 185.61
• InChiKey: CHNDDZHCDWICGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-chloro-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-ol 在 四(三苯基膦)钯 、 草酰氯 、 二甲基亚砜 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 1.5h， 生成 7-(phenylethynyl)-2H-pyrano[2,3-b]pyridin-4(3H)-one
  参考文献：
  名称：

  Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5)

  摘要：

  Novel in vitro mGlu(5) positive allosteric modulators with good potency, solubility, and low lipophilicity are described. Compounds were identified which did not rely on the phenylacetylene and carbonyl functionalities previously observed to be required for in vitro activity. Investigation of the allosteric binding requirements of a series of dihydroquinolinone analogs led to phenylacetylene azachromanone 4 (EC50 11.5 nM). Because of risks associated with potential metabolic and toxicological liabilities of the phenylacetylene, this moiety was successfully replaced with a phenoxymethyl group (27; EC50 156.3 nM). Derivation of a second-generation of mGlu(5) PAMs lacking a ketone carbonyl resulted in azaindoline (33), azabenzimidazole (36), and N-methyl 8-azaoxazine (39) phenylacetylenes. By scoping nitrogen substituents and phenylacetylene replacements in 39, we identified phenoxymethyl 8-azaoxazine 47 (EC50 50.1 nM) as a potent and soluble mGlu(5) PAM devoid of both undesirable phenylacetylene and carbonyl functionalities. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.027
• 作为产物：
  描述：

  3-(tert-butyldimethylsilyloxy)-1-(2,6-dichloropyridin-3-yl)propan-1-ol 在 potassium tert-butylate 、 四丁基氟化铵 、 叔丁醇 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 7-chloro-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-ol
  参考文献：
  名称：

  Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5)

  摘要：

  Novel in vitro mGlu(5) positive allosteric modulators with good potency, solubility, and low lipophilicity are described. Compounds were identified which did not rely on the phenylacetylene and carbonyl functionalities previously observed to be required for in vitro activity. Investigation of the allosteric binding requirements of a series of dihydroquinolinone analogs led to phenylacetylene azachromanone 4 (EC50 11.5 nM). Because of risks associated with potential metabolic and toxicological liabilities of the phenylacetylene, this moiety was successfully replaced with a phenoxymethyl group (27; EC50 156.3 nM). Derivation of a second-generation of mGlu(5) PAMs lacking a ketone carbonyl resulted in azaindoline (33), azabenzimidazole (36), and N-methyl 8-azaoxazine (39) phenylacetylenes. By scoping nitrogen substituents and phenylacetylene replacements in 39, we identified phenoxymethyl 8-azaoxazine 47 (EC50 50.1 nM) as a potent and soluble mGlu(5) PAM devoid of both undesirable phenylacetylene and carbonyl functionalities. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.01.027

文献信息

• [EN] SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS D'OXOISOINDOLINE SUBSTITUÉS POUR LE TRAITEMENT DU CANCER
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021194914A1

  公开（公告）日：2021-09-30

  Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  揭示了化合物的结构式（I）或其盐，其中环A是一个碳链环；环A，R1和n在此处有定义。还揭示了使用这些化合物抑制Helios蛋白的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病（如癌症）方面具有用途。
• [EN] HETEROCYCLIC COMPOUNDS AS HPK1 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE HPK1
  申请人：GUANGDONG NEWOPP BIOPHARMACEUTICALS CO LTD

  公开号：WO2022188735A1

  公开（公告）日：2022-09-15

  Provided are heterocyclics as inhibitors of HPK1, in particular a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that is useful for treatment of HPK1 mediated diseases and conditions such as cancer.

  本文提供了作为 HPK1 抑制剂的杂环化合物，特别是式 I 的化合物或其药学上可接受的盐，以及包含所述化合物的药物组合物，可用于治疗 HPK1 介导的疾病和病症，如癌症。